Patents by Inventor Inna Dashevsky

Inna Dashevsky has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • INTRANASAL DELIVERY OF OLANZAPINE BY PRECISION OLFACTORY DEVICE
    Publication number: 20230364010
    Abstract: Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (Cmax) of at least 30 ng/mL, with (b) a mean time to Cmax (Tmax) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.
    Type: Application
    Filed: July 24, 2023
    Publication date: November 16, 2023
    Inventors: John D. Hoekman, Kelsey H. Satterly, Inna Dashevsky, Aditya R. Das
  • RESPIRATORY TRACT DELIVERY OF LEVODOPA AND DOPA DECARBOXYLASE INHIBITOR FOR TREATMENT OF PARKINSON'S DISEASE
    Publication number: 20230301955
    Abstract: A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.
    Type: Application
    Filed: May 6, 2023
    Publication date: September 28, 2023
    Inventors: John D. Hoekman, Kelsey H. Satterly, Inna Dashevsky, Aditya R. Das, Stephen B. Shrewsbury, Gregory J. Davies, Bhavin Y. Gajera
  • Intranasal delivery of olanzapine by precision olfactory device
    Patent number: 11752100
    Abstract: Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (Cmax) of at least 30 ng/mL, with (b) a mean time to Cmax (Tmax) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.
    Type: Grant
    Filed: January 12, 2022
    Date of Patent: September 12, 2023
    Assignee: Impel Pharmaceuticals Inc.
    Inventors: John D. Hoekman, Kelsey H. Satterly, Inna Dashevsky, Aditya R. Das
  • Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's disease
    Patent number: 11690819
    Abstract: A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.
    Type: Grant
    Filed: February 28, 2022
    Date of Patent: July 4, 2023
    Assignee: Impel Pharmaceuticals Inc.
    Inventors: John D. Hoekman, Kelsey H. Satterly, Inna Dashevsky, Aditya R. Das, Stephen B. Shrewsbury, Gregory J. Davies, Bhavin Y. Gajera
  • Respiratory tract delivery of levodopa and DOPA decarboxylase inhibitor for treatment of Parkinson's Disease
    Patent number: 11517548
    Abstract: A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.
    Type: Grant
    Filed: July 19, 2019
    Date of Patent: December 6, 2022
    Assignee: Impel Pharmaceuticals Inc.
    Inventors: John D. Hoekman, Kelsey H. Satterly, Inna Dashevsky, Aditya R. Das, Stephen B. Shrewsbury, Gregory J. Davies, Bhavin Y. Gajera
  • INTRANASAL DELIVERY OF LEVODOPA POWDER BY PRECISION OLFACTORY DEVICE
    Publication number: 20220296504
    Abstract: Methods are provided for treating OFF episodes in a patient with Parkinson's disease or a Parkinson syndrome, comprising administering to a subject with Parkinson's disease or a Parkinson syndrome experiencing an OFF episode an effective dose of a dry pharmaceutical composition comprising L-DOPA, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma levodopa concentration (Cmax) of at least 200 ng/mL, with (b) a mean time to Cmax (Tmax) of levodopa of less than or equal to 60 minutes. Dry pharmaceutical compositions of levodopa suitable for intranasal administration and unit dosage forms comprising the dry pharmaceutical compositions are also provided.
    Type: Application
    Filed: October 11, 2021
    Publication date: September 22, 2022
    Inventors: John D. Hoekman, Kelsey H. Satterly, Inna Dashevsky, Aditya R. Das, Stephen B. Shrewsbury
  • RESPIRATORY TRACT DELIVERY OF LEVODOPA AND DOPA DECARBOXYLASE INHIBITOR FOR TREATMENT OF PARKINSON'S DISEASE
    Publication number: 20220233486
    Abstract: A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.
    Type: Application
    Filed: February 28, 2022
    Publication date: July 28, 2022
    Inventors: John D. Hoekman, Kelsey H. Satterly, Inna Dashevsky, Aditya R. Das, Stephen B. Shrewsbury, Gregory J. Davies, Bhavin Y. Gajera
  • INTRANASAL DELIVERY OF OLANZAPINE BY PRECISION OLFACTORY DEVICE
    Publication number: 20220183965
    Abstract: Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (Cmax) of at least 30 ng/mL, with (b) a mean time to Cmax (Tmax) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.
    Type: Application
    Filed: January 12, 2022
    Publication date: June 16, 2022
    Inventors: John D. Hoekman, Kelsey H. Satterly, Inna Dashevsky, Aditya R. Das
  • Intranasal delivery of olanzapine by precision olfactory device
    Patent number: 11278492
    Abstract: Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (Cmax) of at least 30 ng/mL, with (b) a mean time to Cmax (Tmax) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: March 22, 2022
    Assignee: Impel Neuropharma, Inc.
    Inventors: John D. Hoekman, Kelsey H. Satterly, Inna Dashevsky, Aditya R. Das
  • RESPIRATORY TRACT DELIVERY OF LEVODOPA AND DOPA DECARBOXYLASE INHIBITOR FOR TREATMENT OF PARKINSON'S DISEASE
    Publication number: 20200046667
    Abstract: A dry pharmaceutical composition is provided that is suitable for respiratory tract delivery of levodopa and DDI for treatment of Parkinson's disease or Parkinson syndrome. The dry pharmaceutical composition comprises levodopa, a dopa decarboxylase inhibitor (DDI) and at least one excipient. A unit dosage form of the dry pharmaceutical composition and a method of treating a patient with Parkinson's disease or Parkinson syndrome by administering the dry pharmaceutical composition are also provided.
    Type: Application
    Filed: July 19, 2019
    Publication date: February 13, 2020
    Inventors: John D. Hoekman, Kelsey H. Satterly, Inna Dashevsky, Aditya R. Das, Stephen B. Shrewsbury, Gregory J. Davies, Bhavin Y. Gajera
  • INTRANASAL DELIVERY OF OLANZAPINE BY PRECISION OLFACTORY DEVICE
    Publication number: 20190240150
    Abstract: Methods are provided for acute treatment of agitation, including agitation in patients with schizophrenia or bipolar disorder, comprising administering to a subject with agitation an effective dose of a dry pharmaceutical composition comprising olanzapine, wherein the dose is administered by an intranasal delivery device that provides, following intranasal administration, (a) a mean peak plasma olanzapine concentration (Cmax) of at least 30 ng/mL, with (b) a mean time to Cmax (Tmax) of olanzapine of less than 0.5 hours. Dry pharmaceutical compositions and devices suitable for intranasal delivery of olanzapine are provided.
    Type: Application
    Filed: January 4, 2019
    Publication date: August 8, 2019
    Inventors: John D. Hoekman, Kelsey H. Satterly, Inna Dashevsky, Aditya R. Das